165 related articles for article (PubMed ID: 21756326)
1. An intracellular targeted antibody detects EGFR as an independent prognostic factor in ovarian carcinomas.
Noske A; Schwabe M; Weichert W; Darb-Esfahani S; Buckendahl AC; Sehouli J; Braicu EI; Budczies J; Dietel M; Denkert C
BMC Cancer; 2011 Jul; 11():294. PubMed ID: 21756326
[TBL] [Abstract][Full Text] [Related]
2. Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer.
Noske A; Weichert W; Niesporek S; Röske A; Buckendahl AC; Koch I; Sehouli J; Dietel M; Denkert C
Cancer; 2008 Apr; 112(8):1733-43. PubMed ID: 18306389
[TBL] [Abstract][Full Text] [Related]
3. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival.
Rubin Grandis J; Melhem MF; Gooding WE; Day R; Holst VA; Wagener MM; Drenning SD; Tweardy DJ
J Natl Cancer Inst; 1998 Jun; 90(11):824-32. PubMed ID: 9625170
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of CRM1 activity sensitizes endometrial and ovarian cell lines to TRAIL-induced cell death.
Fabi F; Adam P; Vincent K; Demontigny F; Parent S; Joncas FH; Asselin E
Cell Commun Signal; 2018 Jul; 16(1):39. PubMed ID: 29973205
[TBL] [Abstract][Full Text] [Related]
5. The growth factor receptors HER-2/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinoma.
Skirnisdóttir I; Sorbe B; Seidal T
Int J Gynecol Cancer; 2001; 11(2):119-29. PubMed ID: 11328410
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of the embryonic-lethal abnormal vision-like protein HuR in ovarian carcinoma is a prognostic factor and is associated with increased cyclooxygenase 2 expression.
Denkert C; Weichert W; Pest S; Koch I; Licht D; Köbel M; Reles A; Sehouli J; Dietel M; Hauptmann S
Cancer Res; 2004 Jan; 64(1):189-95. PubMed ID: 14729623
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical localization of c-erbB-2 protein and epidermal growth factor receptor in normal surface epithelium, surface inclusion cysts, and common epithelial tumours of the ovary.
Wang DP; Konishi I; Koshiyama M; Nanbu Y; Iwai T; Nonogaki H; Mori T; Fujii S
Virchows Arch A Pathol Anat Histopathol; 1992; 421(5):393-400. PubMed ID: 1360720
[TBL] [Abstract][Full Text] [Related]
8. The expression of DBC1/CCAR2 is associated with poor prognosis of ovarian carcinoma.
Cho D; Park H; Park SH; Kim K; Chung M; Moon W; Kang M; Jang K
J Ovarian Res; 2015 Feb; 8():2. PubMed ID: 25823848
[TBL] [Abstract][Full Text] [Related]
9. The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients.
Gayarre J; Kamieniak MM; Cazorla-Jiménez A; Muñoz-Repeto I; Borrego S; García-Donas J; Hernando S; Robles-Díaz L; García-Bueno JM; Ramón Y Cajal T; Hernández-Agudo E; Heredia Soto V; Márquez-Rodas I; Echarri MJ; Lacambra-Calvet C; Sáez R; Cusidó M; Redondo A; Paz-Ares L; Hardisson D; Mendiola M; Palacios J; Benítez J; García MJ
J Gynecol Oncol; 2016 Jan; 27(1):e7. PubMed ID: 26463438
[TBL] [Abstract][Full Text] [Related]
10. Immunolocalization of epidermal growth factor receptor and c-erbB-2 oncogene product in human ovarian carcinoma.
Ito K; Sasano H; Ozawa N; Sato S; Silverberg SG; Yajima A
Int J Gynecol Pathol; 1992 Oct; 11(4):253-7. PubMed ID: 1356938
[TBL] [Abstract][Full Text] [Related]
11. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
12. Expression of hypoxia-inducible factor 1alpha, hypoxia-inducible factor 2alpha, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1alpha is an independent prognostic factor in ovarian carcinoma.
Osada R; Horiuchi A; Kikuchi N; Yoshida J; Hayashi A; Ota M; Katsuyama Y; Melillo G; Konishi I
Hum Pathol; 2007 Sep; 38(9):1310-20. PubMed ID: 17555795
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Impact of Membranous/Nuclear Epidermal Growth Factor Receptor Localization in Clear Cell Renal Cell Carcinoma.
Muroni MR; Ribback S; Sotgiu G; Kroeger N; Saderi L; Angius A; Cossu-Rocca P; De Miglio MR
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445451
[TBL] [Abstract][Full Text] [Related]
14. Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma.
Izquierdo MA; van der Zee AG; Vermorken JB; van der Valk P; Beliën JA; Giaccone G; Scheffer GL; Flens MJ; Pinedo HM; Kenemans P
J Natl Cancer Inst; 1995 Aug; 87(16):1230-7. PubMed ID: 7563169
[TBL] [Abstract][Full Text] [Related]
15. Topoisomerase IIalpha mRNA and protein expression in ovarian carcinoma: correlation with clinicopathological factors and prognosis.
Faggad A; Darb-Esfahani S; Wirtz R; Sinn B; Sehouli J; Könsgen D; Lage H; Weichert W; Noske A; Budczies J; Müller BM; Buckendahl AC; Röske A; Eldin Elwali N; Dietel M; Denkert C
Mod Pathol; 2009 Apr; 22(4):579-88. PubMed ID: 19270648
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical detection of HSP60-expression in human ovarian cancer. Correlation with survival in a series of 247 patients.
Schneider J; Jiménez E; Marenbach K; Romero H; Marx D; Meden H
Anticancer Res; 1999; 19(3A):2141-6. PubMed ID: 10470162
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells.
Alper O ; Bergmann-Leitner ES; Bennett TA; Hacker NF; Stromberg K; Stetler-Stevenson WG
J Natl Cancer Inst; 2001 Sep; 93(18):1375-84. PubMed ID: 11562388
[TBL] [Abstract][Full Text] [Related]
18. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma.
Levesque MA; Katsaros D; Yu H; Zola P; Sismondi P; Giardina G; Diamandis EP
Cancer; 1995 Mar; 75(6):1327-38. PubMed ID: 7882283
[TBL] [Abstract][Full Text] [Related]
19. Novel reversible selective inhibitor of CRM1 for targeted therapy in ovarian cancer.
Liu X; Chong Y; Liu H; Han Y; Niu M
J Ovarian Res; 2015 Jun; 8():35. PubMed ID: 26055813
[TBL] [Abstract][Full Text] [Related]
20. Expression of CRM1 and CDK5 shows high prognostic accuracy for gastric cancer.
Sun YQ; Xie JW; Xie HT; Chen PC; Zhang XL; Zheng CH; Li P; Wang JB; Lin JX; Cao LL; Huang CM; Lin Y
World J Gastroenterol; 2017 Mar; 23(11):2012-2022. PubMed ID: 28373767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
